This within-subject, double blind, randomized controlled study will investigate the effects
of a widely used benzodiazepine (BZD), lorazepam, on various neuroimaging measures. The
investigators will be assessing the relationship of lorazepam to resting state functional
connectivity and other neuroimaging measures. Specifically, the investigators will be using a
pre-identified metric, the striatal connectivity index (SCI), (Sarpal et al. 2015, 2016), a
prognostic biomarker of treatment response assessing the connectivity between regions of the
striatum and the cortex. The investigators hypothesize that lorazepam administration will be
associated with greater SCI values compared with placebo administration; consistent with
previous work suggesting short-acting benzodiazepines increase functional connectivity across
brain networks.